 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Imunon, Inc. (NASDAQ:IMNN  Get Free Report) was the target of a significant decline in short interest in November. As of November 15th, there was short interest totalling 10,600 shares, a...

Imunon, Inc. (NASDAQ:IMNN) Short Interest Update

Imunon, Inc. (NASDAQ:IMNN  Free Report)  Equities researchers at Brookline Capital Management lifted their FY2023 earnings per share estimates for shares of Imunon in a report released...

Imunon, Inc. Forecasted to Earn FY2023 Earnings of ($2.25) Per Share (NASDAQ:IMNN)

Imunon, Inc. (IMNN) Q3 2023 Earnings Call Transcript...

Imunon, Inc. (IMNN) Q3 2023 Earnings Call Transcript

Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON's PlaCCine modality and its applicability to multiple pathogens LAWRENCEVILLE, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE...

IMUNON's VP of R&D to Present at the Vaccines Summit-2023

Imunon GAAP EPS of -$0.37 beats by $0.29...

Imunon GAAP EPS of -$0.37 beats by $0.29

Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Conference Call Begins...

IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update

LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Imunon CSO to present at third International Vaccines Congress

Highlights advantages of IMUNON's PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...

IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress

A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics presented by the Foreign Policy Association LAWRENCEVILLE, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...

IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Market Cap	$8.18M
Volume (M)	7,909.00
52-Wk High	$1.72
52-Wk Low	$0.8448

IMNN Imunon Inc

About

Feed

News

Fundamentals